003022 联泓新科
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入4,568,189-8.02%6,267,9146,777,5858,156,9917,580,763
减:营业总成本4,325,039-12.15%6,190,9836,578,2677,472,5266,553,468
    其中:营业成本3,678,552-12.52%5,233,6555,682,3546,507,5105,675,312
               财务费用89,12627.76%88,44586,929115,520140,326
               资产减值损失(11,015)-295.23%(7,444)(41,886)(12,277)(1,688)
公允价值变动收益252-1.88%34048696512,741
投资收益1,838-108.60%41,391(2,785)1,61429,658
    其中:对联营企业和合营企业的投资收益1,496-3,681.25%(149)(485)(227)3,099
营业利润277,18726.71%317,880519,154860,3341,269,348
利润总额276,63639.91%301,464520,879857,8661,270,066
减:所得税费用37,29760.40%35,71464,646(16,030)164,313
净利润239,33937.18%265,749456,234873,8951,105,753
减:非控股权益6,932-279.22%31,30710,1107,64715,183
股东净利润232,40730.32%234,443446,123866,2481,090,570

市场价值指针
每股收益 (元) *0.17030.77%0.1800.3300.6500.820
每股派息 (元) *----0.0600.0800.2000.200
每股净资产 (元) *5.5252.61%5.4235.3325.1944.744
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容